Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

FIP world congress 2025

FIP world congress 2025, themed “Pharmacy Forward: Performance, Collaboration, and Health Transformation,” aims to explore the evolving role of the pharmacy profession in the context of modern healthcare challenges. FIP world congress 2025, themed...

ISPE Singapore Conference & Exhibition 2025

The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most respected pharmaceutical manufacturing shows in Singapore for pharmaceutical and biomanufacturing professionals. The ISPE Singapore Affiliate Conference &...

13th World Conference on Pharmaceutical Science and Drug Manufacturing (WCPD) 2025

13th World Conference on Pharmaceutical Science and Drug Manufacturing (WCPD) 2025 hosted by IFERP Life Sciences will offer a diverse range of topics, from drug discovery and development to clinical trials, applications and healthcare delivery....

New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

any artificial additives. The results of this study—drawn from a double-blind national survey of U.S. pediatricians (FRC 2025) — found that an overwhelming majority of respondents prefer Genexa’s oral suspension ingredient profiles for treating...

Viatris announces the approval of the first generic iron sucrose injection in the U.S

upon commercial marketing of the medicine. Venofer® had annual sales of approximately $515M in the U.S. as of June 30, 2025, according to IQVIA. Iron Sucrose Injection, For Intravenous Use INDICATION AND USAGE Iron sucrose injection is indicated...

Jazz Pharmaceuticals announces the U.S. FDA approval of Modeyso™ (dordaviprone) as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma

following radiotherapy.6 Modeyso was developed by Chimerix prior to its acquisition by Jazz Pharmaceuticals in April 2025. DRUG INTERACTIONS Strong and Moderate CYP3A4 Inhibitors Avoid concomitant use of MODEYSO with strong and moderate CYP3A4...

Avenacy Unveils the Launch of Dehydrated Alcohol Injection, USP Vials in the U.S. Market

USP in the United States as a therapeutic generic equivalent of Ablysinol®, which ended its market exclusivity in June 2025. Dehydrated Alcohol Injection is indicated to induce controlled cardiac septal infarction to improve exercise capacity in...

Cronus Pharma Launches Butorphic® (Butorphanol Tartrate) as a Sterile Injectable Solution

marks our fifth product launch this year, expanding our portfolio to twenty-five products with several more planned for 2025 and beyond," said Vimal Kavuru, Chairman & CEO. This launch enhances Cronus Pharma's robust sedative and anesthesia product...

Australia Regulatory Device Summit 2025

of Australia (MTAA) are excited to collaborate for the first time to jointly produce Australia Regulatory Device Summit 2025, convening 17-18 July at ICC Sydney in Sydney, Australia. This two-day event will unite experts from Therapeutic Goods...

TrueMed Partners with Alliance Pharmaceuticals Ltd to Combat Sophisticated Counterfeits Using AI-Powered Authentication

strategy leveraging TrueMed's digital authentication technology to identify and act on threats instantly. "You can't fight 2025 counterfeits with 2010 tools," said Jyrki Berg, CEO of TrueMed. "Our collaboration with Alliance Pharmaceuticals Ltd...

Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 Begins with First Patient Dosed

novel EGFR/HER3 bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors. On January 7th, 2025, DualityBio and Avenzo announced that they have entered into an exclusive license agreement, pursuant to which Avenzo will...

Seraphina Therapeutics Announces C15:0 Reverses Key Aspects of Cellular Fragility Syndrome in a Second Model

said Dr. Stephanie Venn-Watson, Co-CEO of Seraphina Therapeutics. Dr. Venn-Watson was recently recognized as a 2025 CNBC Changemaker for her research on C15:0's essentiality and the discovery of Cellular Fragility Syndrome. In 2020, C15:0...

Precision In Clinical Trials Summit Zurich Europe 2025

providers, the summit is designed to help attendees find solutions to their most pressing clinical trial challenges in 2025 and beyond.

Neurocrine Biosciences Presents New Post-Hoc Data from the KINECT®-HD Study, Demonstrating a Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

monoamine transporter 2 inhibitor (INGREZZA) in patients treated for chorea. These analyses will be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders Congress hosted by the Parkinson & Movement Disorder Alliance in...

Innovent Announces Approval from China's NMPA for Mazdutide, the First Dual GCG/GLP-1 Receptor Agonist, for Chronic Weight Management

comprehensive metabolic benefits, named by Fierce Pharma as one of the top ten most anticipated drugs globally in 2025. The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate...

Webinar : Leverage AI for Operational Excellence and Strategic Cost Management

Join The Hackett Group and functional and operations leaders to supercharge business change and performance, while leveraging AI for maximum impact. Prepare for Industry Headwinds and Enhance Operational Excellence in Pharma Over the next 5 years,...

Kashiv BioSciences Announces Positive Topline Results from the Confirmatory Efficacy Study of ADL-018, a Biosimilar Candidate to XOLAIR® (omalizumab).

(BLA) for this product is expected to be filed with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025. The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has already validated and accepted the marketing...

3rd Global Pharma Tech Summit 2025

The Global Pharma Tech Summit 2025 would like to welcome all the pharmaceutical professionals and companies to speak at our prestigious Pharma Summit 2024 slated on June 23 - 24, 2025. The Global Pharma Tech Summit 2025 would like to welcome all...

Boehringer Ingelheim and the Lung Cancer Research Foundation Announce New Research Collaboration

for Proposals will be reviewed through a two-step process: Letters of Intent will be accepted until midnight on July 29, 2025; if selected, projects will then be chosen to submit full proposals. All applications will be subject to a rigorous review...

Dupixent® outperformed Xolair® in treating CRSwNP with asthma in the first Phase 4 head-to-head trial

head-to-head respiratory trial with biologic medicines and were shared in a late-breaking oral presentation at the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. “Patients suffering from chronic rhinosinusitis...

Results 1 - 20 of 96